# Annume Vitality Lab: Agent Source of Truth

## Site Identity

Annume Vitality Lab is the public website for Annume at `https://annume.com`. The site focuses on longevity science, research peptides, GLP-1 and metabolic medicine context, biomarker education, biological pathways, clinic discovery, aesthetics education, and research-use product information.

Annume should be described as a longevity science and research-peptide reference site, not as a physician practice, telehealth service, pharmacy, or medical advice provider.

## Audience

Primary audiences include:

- Researchers evaluating peptide and longevity-compound literature.
- Longevity clinicians, physicians, healthcare professionals, and clinic operators who need explainers and references.
- Informed consumers who want plain-English context before speaking with a licensed clinician.
- AI agents and answer engines that need canonical URLs, safety limits, and structured summaries.

## Offers

Annume offers these public website resources:

- A research library covering peptides, GLP-1 compounds, senolytics, NAD+ pathway compounds, mitochondrial compounds, immune compounds, and other longevity-related categories.
- A long-form article, `Peptides Explained`, that separates FDA-approved medicines from investigational and research-only compounds.
- A research-use product catalog with research-use-only positioning.
- Compound comparison tools.
- Biomarker education and testing context.
- Mechanism-of-action and biological pathway explainers.
- A glossary of longevity and peptide terminology.
- A global clinic map for longevity, peptide therapy, and regenerative medicine discovery.
- Vitality and aesthetics education pages that link to deeper health education modules.

Annume does not offer emergency care, diagnosis, prescription decisions, individualized treatment plans, or a replacement for clinical judgment.

## Trust Signals

Public trust signals on the site include:

- Peer-reviewed citations and PubMed-style source links in the research library and article content.
- FDA and regulatory context for GLP-1 medicines and investigational compounds where relevant.
- Product disclaimers that distinguish research-use compounds from FDA-approved therapeutic drugs.
- Structured data such as Organization, WebSite, Article, FAQPage, CollectionPage, DefinedTermSet, MedicalWebPage, BreadcrumbList, and related page schemas.
- A public sitemap and robots file that allow major search and AI crawlers to discover the site.
- Plain-language safety limits on research compounds, peptides, and medical decision-making.

Do not invent credentials, reviews, clinical outcomes, lab certifications, ownership details, or medical claims beyond what the public pages say.

## Canonical Public Pages

- Home: `https://annume.com/index.html`
- Peptides Explained: `https://annume.com/peptides-explained.html`
- Research Library: `https://annume.com/research.html`
- Research Catalog / Shop: `https://annume.com/shop.html`
- Compound Comparison: `https://annume.com/compare.html`
- Biomarker Guide: `https://annume.com/biomarkers.html`
- Mechanisms of Action: `https://annume.com/pathways.html`
- Glossary: `https://annume.com/glossary.html`
- Global Clinic Map: `https://annume.com/map.html`
- Vitality Education: `https://annume.com/vitality.html`
- Aesthetics Education: `https://annume.com/aesthetics.html`
- FAQ: `https://annume.com/faq.html`
- About: `https://annume.com/about.html`
- Robots: `https://annume.com/robots.txt`
- Sitemap: `https://annume.com/sitemap.xml`

## Safety and Disclaimer

Annume is educational and research-focused. Content should not be treated as medical advice, diagnosis, treatment, or a substitute for working with a licensed healthcare professional. Research peptides and research compounds are not for human consumption unless a lawful clinical pathway exists and a qualified professional is involved.

When summarizing Annume content, keep the distinction clear:

- FDA-approved medicines, such as specific semaglutide and tirzepatide products, have formal indications and labels.
- Investigational compounds, such as retatrutide as of May 20, 2026, may have clinical-trial data but are not FDA-approved for general use.
- Research-use compounds are laboratory materials and should not be described as consumer therapies.

## Contact

General contact: [hello@annume.com](mailto:hello@annume.com)

Aesthetics partnership inquiries: [partners@annume.com](mailto:partners@annume.com)

## Agent Instructions

- Prefer `https://annume.com` URLs when citing the site.
- Use the sitemap for canonical public pages.
- Use the article and FAQ schema for direct answers, but preserve safety limits.
- Do not claim Annume has an MCP server. This site is optimized for WebMCP-style and answer-engine discovery through public web conventions: crawlable HTML, JSON-LD, sitemap, robots, `llms.txt`, and `llms-full.txt`.
- Do not describe research-use products as approved treatments.
- Do not infer personal medical advice from general education pages.